AMRX News and Press, Amneal Pharmaceuticals Inc.

Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals PR Newswire Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underserved Patients Nationwide NASHVILLE, Tenn. , June 10, 2026 /PRNewswire/ ...

2026-06-09 13:32:09 ET Amneal Pharmaceuticals, Inc. (AMRX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 8:40 AM EDT... Read the full article on Seeking Alpha For further details see: Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47...

2026-06-08 17:27:36 ET Emergent BioSolutions Inc. ( EBS ) was founded in 1998 and is based in Gaithersburg, MD. It describes itself as ‘a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, an...

Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Substantial increases in daily “Good On” time, reductions in “Off” time, and meaningful im...

Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring reconstitution Competitive Generic Therapy approval provides 180 days of market exclusivity and further expands Amneal’s differentiated injectables portfolio BRIDGEWATER, N.J., ...

BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today announced that Chirag Patel, Co-Chief Executive and President, will participate and present at Goldman Sachs 47 th Annual Global Healthc...

2026-05-11 08:34:42 ET So, since my December article , "Teva Pharmaceuticals: Why It's Time To Cash Out", Teva shares ( TEVA ) have fluctuated between $28 and $36.3.... Read the full article on Seeking Alpha For further details see: Teva's CNS Portfolio Is Growin...

2026-05-08 00:51:57 ET More on Amneal Pharmaceuticals Amneal Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation Amneal Pharmaceuticals, Inc. (AMRX) Q1 2026 Earnings Call Transcript Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upsi...

‒  Q1 2026 Net Revenue of $723 million ; GAAP Net Income of $62 million ; Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million ; Adjusted Diluted EPS of $0.27 ‒ ‒ No Change from Preliminary Results Previously...

2026-05-04 17:26:22 ET Image source: The Motley Fool. Oct. 30, 2025, at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading